Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5A-IL2 Immunocytokine and SBRT in Metastatic Colorectal or Breast Cancer
NCT06130826Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- May 2025
- Primary completion
- Mar 2029
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M5A-IL2 in colorectal cancer (CRC) and breast cancer, sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Started May 2025; status: recruiting.
02
Drugs
M5A-IL2
03
Conditions
colorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT06130826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130826.